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Abstract
Objectives An N-of-1 trial is a double-blind placebo-
controlled randomized trial to objectively and systematical-
ly evaluate the individual’s response. This approach seems
extraordinarily suitable for assessing the efficacy of
stimulants in the treatment of attention deficit hyperactivity
disorder (ADHD). The aim is to examine the use of N-of-1
trials among youths in the Netherlands, the protocols used,
and the continuation of stimulant treatment thereafter.
Methods Physicians requesting N-of-1 trials with stimu-
lants were interviewed about their rationale and protocol.
Prevalence and continuation were investigated by extract-
ing N-of-1 trials among youths <20 years of age from a
large pharmacy dispensing database for 2000–2004.
Results The main purpose of N-of-1 trials mentioned by
physicians was the assessing of individuals’ response and
dose-finding. Trial length, dosing schedule and efficacy
assessment differed per physician. Trials consisted of a
maximum of two treatment periods per dose. The annual
percentage of youths starting stimulant treatment with an N-
of-1 trial fluctuated between 0.6% (3/462) and 3.3% (10/
301). No statistical significant difference could be detected
between the continuation of stimulant treatment with or
without an N-of-1 trial (p=0.71).
Conclusions N-of-1 trials with stimulants are infrequently
and not optimally used in the Netherlands. The results of N-of-
1 protocols described by physicians are of questionable value,
due to the small number of treatment periods per dose. More
uniformity in the protocols would make it easier to encompass
the N-of-1 methodology in physicians’ daily practice.
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Introduction
In many Western countries, the use of stimulants among
youths has increased markedly in the last decade [16, 19,
21, 29]. Stimulants are the first-choice medication in the
treatment of attention deficit hyperactivity disorder
(ADHD). In 70–80% of the youths, stimulants reduce
hyperactivity, impulsiveness and inattentiveness [2]. ADHD
was once thought to disappear as children grew up, but
follow-up studies in youths with ADHD have shown
considerable persistence of the disorder into adulthood [5,
3]. For these patients, long-term treatment with stimulants
may be indicated. The impact of long-term stimulant use,
however, is still unclear [10].
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As up to 30% of youths will not respond to stimulant
treatment [2], it is important to evaluate the effect of
stimulant treatment in the individual child at an early stage
of treatment. A useful method that helps the physician and
family to evaluate the effect of medication in individuals is
the N-of-1 or single-subject trial [4, 8]. An N-of-1 trial is a
double-blind placebo-controlled randomized trial to objec-
tively and systematically assess individual response. In an
N-of-1 trial, a single patient undergoes a series of cross-
overs with active treatment/placebo, high dose/low dose or
first choice/alternative treatment. The order of administra-
tion is determined by random allocation and the patient and
physician are blinded for the treatment order. Target
symptoms are assessed and interpreted afterwards. The N-
of-1 methodology is not suitable for all disorders and
pharmacological treatments. Apart from the benefit-risk
balance of the treatment being in doubt, the disorder should
be chronic and relatively stable. Furthermore, treatment
must have a rapid onset and termination of action, ruling
out carry-over effect into the next treatment period.
An N-of-1 trial seems ideal for evaluating the efficacy of
the stimulant methylphenidate in youths diagnosed with
ADHD. First, ADHD is nowadays considered a chronic
disorder, showing rather consistent symptoms. Second,
methylphenidate has a rapid onset (.5–1 h) and termination
of action (4–6 h) [23]. Furthermore, rational evaluation of
behaviour is hard, and the placebo-controlled double-blind
design enables a more objective evaluation of behavioural
changes due to medication [4].
Several papers on stimulant treatment making use of the
N-of-1 methodology have been published. The methodology
was used for dose-finding and evaluation of side effects in
several clinical trials on stimulant treatment in youths with
ADHD [1, 18, 24]; however, in these papers, the N-of-1
methodology received no further attention. Parental accep-
tance, satisfaction and compliance of methylphenidate
treatment after an N-of-1 trial were investigated by Johnston
and Fine [11]. Other studies illustrated how N-of-1 trials with
methylphenidate can be used in routine clinical practice [6,
14, 17] and Kent et al. promoted the technique as practical,
useful and highly endorsed by families [13]. Furthermore, in
the literature, several suggestions have been proposed to
enhance reliable and unbiased interpretation of the effect of
medication such as assigning consistent raters, tailoring the
outcome measures, blind evaluation of trial outcome and the
use of statistical tests [4, 20, 26].
Most studies on the use of N-of-1 trials in stimulant
treatment in clinical practice were limited to single clinics
in North America [6, 11, 13, 14]. As far as we know, no
research has been done to examine the frequency of use of
N-of-1 trials with stimulants in the general paediatric
population. In this study, we examined the occurrence of
N-of-1 trials when starting stimulant treatment in The
Netherlands, and interviewed physicians about their proto-
cols. Using this information, we derived the proportion of
stimulant treatments, starting with an N-of-1 trial, and the
continuation of stimulant treatment using pharmacy data.
Methods
The data sources used included physicians and a large
pharmacy-dispensing database.
Physicians’ interviews
To reach physicians conducting N-of-1 trials with stimu-
lants for an interview, a brief questionnaire was sent to 102
randomly selected pharmacies. Pharmacists play an essen-
tial role in performing an N-of-1 trial because they prepare
the blinded stimulant and placebo capsules. Pharmacists
were asked if they had provided an N-of-1 trial with
stimulants in the past year. If so, pharmacists were asked for
names of physicians who had requested an N-of-1 trial.
Then the physicians were called to ask to participate in an
interview. The questions asked were about their consid-
erations in using the N-of-1 method in stimulant treatment
and details of the protocols used. During the interview, the
physicians were given ample opportunity to provide
additional information about their N-of-1 method. Informa-
tion about these protocols was used to identify N-of-1 trials
in the database part of the study. During the major part of
the study period, short-acting methylphenidate and dexam-
phetamine were the available and reimbursed stimulants on
the Dutch market. Long-acting methylphenidate became
available without regular reimbursement at the end of 2003.
Database study
The quantitative part of this study was performed with the
InterAction database (IADB), which contains prescription
drug dispensing data from about 50 community pharmacies
in the northern and eastern part of the Netherlands. The
IADB covers all prescriptions from an estimated population
of approximately 450,000 since 1999 [22, 25]. This
database includes all prescriptions, regardless of prescriber,
insurance, or reimbursement status, apart from over-the-
counter drugs and drugs dispensed during a hospital stay.
Each prescription record comprises information about the
drug, date of dispensing, amount dispensed, dose regimen
and the prescribing physician. All drugs are coded accord-
ing to ATC-classification. Each patient has a unique, though
anonymous, identifier. Due to a high patient-pharmacy
commitment in the Netherlands and sophisticated pharmacy
software, the medication records for each patient are
virtually complete [15].
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From the IADB, we derived a study population of all
incident stimulant users aged 0–19 years with a first-time
prescription of stimulants dispensed during 2000–2004.
Youths were regarded as incident users if they received a
stimulant prescription, without having had any stimulant
prescriptions in the preceding year, while being registered
in the IADB. Data from 1999 were used to identify incident
users in 2000.
Based on information on the N-of-1 protocols from the
physician interviews, potential N-of-1 trials were defined as
dispension of at least two prescriptions for compounded
stimulant capsules and other compounded capsules to the
same person from the same pharmacy within a time frame of
1 month. Medication profiles of ten selected patients from the
IADB receiving a potential N-of-1 trial with stimulants were
presented to four pharmacists. Within this group, consensus
was quickly reached about what could be considered an N-of-
1 trial at the start of stimulant treatment. Criteria were: (1)
dispension of compounded methylphenidate capsules and
placebo capsules with inert excipients like lactose powder or
cornstarch only, (2) within a time frame of 2 weeks (3) to one
person (4) from the same pharmacy. From the medication
profiles of the incident stimulant users in the IADB, N-of-1
trials with methylphenidate were extracted using the criteria
above. Since more than 99% of the incident stimulant users in
the Netherlands receive methylphenidate [7], we only
considered N-of-1 trials with methylphenidate. Of the
initially 46 potential N-of-1 trials detected, 31 satisfied all
four criteria. All 15 excluded cases received compounded
capsules with adjunct medication besides stimulant capsules
and had received no placebo capsules.
The percentage of incident users starting stimulant
treatment with an N-of-1 trial per total number of incident
stimulant users was estimated per year. Continuation of
stimulant treatment after an N-of-1 trial was compared to
other starters using Kaplan-Meier survival estimators.
Stimulant treatment was considered discontinued when a
youth had not received stimulant prescriptions for at least
365 consecutive days after the dispension date of the final
prescription plus half the number of days of the final
prescription. A log-rank test was used to test for overall
differences in the continuation of therapy between starting
treatment with and without an N-of-1 trial. Statistical tests
were considered significant when p<0.05 (two-tailed).
Results
Physicians’ interviews
Of 102 pharmacists to whom a questionnaire was sent, 51
responded of whom 24 pharmacists were able to mention
names of 14 physicians requesting an N-of-1 trial in the
past year. The 9 remaining pharmacists were unwilling or
unable to give a name (e.g. only institute name available or
physician moved office). Fourteen physicians were
approached for an interview. One child psychiatrist and
one paediatrician were not willing to participate due to busy
schedules. The remaining 12 physicians were interviewed;
7 child psychiatrists, 1 adult psychiatrist, 2 paediatricians, 1
youth health care physician and one family doctor.
Eight physicians (8/12 or 67%) perceived the N-of-1
methodology as a customary procedure when stimulant
treatment was considered (Table 1). One physician also
used the method to evaluate continuation of stimulant
treatment. The main purpose for conducting an N-of-1
trial was assessing individuals’ response to stimulants and
examining the optimal dose for most of the interviewed
physicians. All physicians used a double-blind placebo-
controlled trial in which the pharmacist was responsible
for the randomization and for preparing the blinded
methylphenidate and placebo capsules. Treatment periods
were applied in random order. No protocol was the same,
as trial length, dosing schedule, frequency of rating
outcome and number of crossover periods differed per
protocol. According to most protocols the parents and
teacher of the child assessed target symptoms during the
trial, and scores were visually evaluated afterwards. The
abbreviated Conners’ parent and teacher rating scales were
used for measuring outcome by 8 of 12 physicians (67%).
Adverse effects were assessed and evaluated in 3 of the 12
protocols (25%).
Database study
Using the pharmacy database IADB, a total of 1,769 youths
starting treatment with stimulants in the period 2000–2004
were detected. The median age was 9 years and the male-to-
female ratio among these starters was 3.4:1. The percentage
starting treatment with an N-of-1 trial with methylphenidate
fluctuated between 0.6% (3/462) and 3.3% (10/301) per
year during 2000–2004 (Table 2). The median age in
youths starting stimulant treatment with an N-of-1 trial
was not statistically different from other starters (for both
groups 9.0 years, p=0.84). The male-to-female ratio
among youths starting stimulant treatment with an N-of-
1 trial was 4.2:1 and did not significantly differ statisti-
cally from the male-to-female ratio in other starters (3.4:1,
p=0.64). After 5 weeks, the cumulative probability of
continuation of stimulant treatment was 0.89 (95%CI
0.77–1.0) among youths starting with an N-of-1 trial and
0.89 (95%CI 0.87–0.91) for other starters (Fig. 1). Also,
no overall statistically significant difference could be
detected between continuation of stimulant treatment in
youths starting with an N-of-1 trial and the other starters
(p=0.71, 1df).
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Discussion
Two thirds of the responding Dutch pharmacists had
provided an N-of-1 trial with stimulants in the last year.
Usually, requests came from child psychiatrists or paedia-
tricians who used the N-of-1 methodology for determining
individuals’ response and dose-finding, and each of these
physicians used his or her own protocol.
Similar to other studies, we found that assessing
individuals’ response and dose-finding were the main
reasons for physicians to apply an N-of-1 trial [11, 13,
14]. Other reasons mentioned in the literature were
discouraging both overenthusiastic prescribing and a priori
rejection of stimulant therapy [14] and positively influenc-
ing parents’ views regarding the acceptability of methyl-
phenidate [11]. The latter was reported by one physician in
our study who performed an N-of-1 trial only in case
parents were reluctant to stimulant treatment.
Although none of the Dutch physicians followed the
same N-of-1 procedure exactly, most of the N-of-1
procedures were roughly similar to the ones used in two
outpatient clinics in Canada [11, 13, 14]. Mostly placebo
and methylphenidate treatment periods of 1 week were
used, different methylphenidate doses were compared and
Conners’ rating scales were used to measure effectiveness.
However, trial length was 3 weeks in the Canadian centres,
while 4 weeks was most commonly found in our study. In
two other North American studies among institutionalized
youths with ADHD, placebo and methylphenidate treat-
ment periods were shorter, as randomization took place per
day or per 4 days, resulting in a trial length of 6–16 days
[14, 26]. Probably in our community setting and in the
Canadian outpatient clinics, treatment periods of 1 week
were chosen because shorter treatment periods were
difficult to implement in an outpatient setting.
The frequency of measuring outcome during an N-of-1
trial varied between daily to weekly ratings in our study, a
variation also found in the literature [11, 13, 14, 26]. We
prefer daily outcome measurements, because in that way,
day-to-day variation in ADHD symptoms and treatment
effect (caused by multiple factors) is represented, some-
thing that is ignored when rating only once a week. After
all, it may be hard to give a well-considered overall
judgment of behaviour at the end of a treatment period of
7 days.
It is of concern that all physicians evaluated the trial
outcome measurements by visual inspection and not by
Table 1 Questions and answers of interviews with physicians (n=12)
conducting N-of-1 trials with methylphenidate
No.
physicians
When do you offer an N-of-1 trial?
Customary procedure if stimulant treatment
is considered
8
If stimulant treatment is considered, but not
as a customary procedure
3
Customary procedure if stimulant treatment is
considered and for evaluation of treatment
1
For what purpose do you use an N-of-1 trial
with stimulants?
Assessing effectiveness and optimal dose
methylphenidate
8
Assessing effectiveness 3
To convince parents who are reluctant to
stimulant treatment
1
Which dosing schedule do you apply?
4 periods of 1 week, comparing placebo
and 3 different doses methylphenidate
5
4 periods of 1 week, comparing placebo
and 2 different doses methylphenidate
4
4 periods of 1 week, comparing placebo
and 1 dose of methylphenidate
1
2 periods of 1 week, comparing placebo
and 1 dose methylphenidate
1
4 periods of 2 weeks, comparing placebo
and 1 dose methylphenidate
1
What is the frequency of dosing during a trial day?
2× per day 11
2 or 3× per day 1
How are target symptoms assessed during
the trial? Use of
Abbreviated Conners’ rating scale 8
Score list (self-made) 2
DSM IVa criteria 1
Diary 1
How often are target symptoms assessed
during the trial?
Daily 6
Weekly 5
Minimal (at least on 2 weekdays and
during the weekend)
1
Do you use an adverse effects questionnaire?
No 9
Yes 3
Do you use statistical tests to interpret the
outcome of the trial?
No 12
a Diagnostic and Statistical Manual of Mental Disorders, 4th edition
Table 2 Prevalence of starting stimulant treatment in youths <20 years
with an N-of-1 trial in the period 2000 to 2004
Year No. of
starters
No. starting with
N-of-1 trial
% starting with
N-of-1 trial
95% CI
2000 313 6 1.9 0.7–4.1
2001 301 10 3.3 1.6–6.0
2002 313 3 1.0 0.2–2.8
2003 380 9 2.4 1.1–4.4
2004 462 3 0.6 0.1–1.9
60 Eur J Clin Pharmacol (2007) 63:57–63
means of a statistical test. A study by Wallace and Koefoed
showed that visual inspection resulted in a greater likeli-
hood that treatments were falsely accepted as effective as is
generally acceptable by a statistical inspection [26].
However, even if statistical tests were used, none of the
N-of-1 protocols described by the physicians appeared to
have had enough cycles of the same treatment to deliver a
statistically significant result, which makes the evaluation
of these N-of-1 trials of questionable value. At least three
cycles of the same treatment are necessary to deliver a
statistically significant result. Adjunct statistical evaluation
of N-of-1 trials is possible though onerous for clinicians [4,
8, 20]. This lack of statistical resource indicates an
opportunity for the development of an N-of-1 service such
as has been available in other countries [9, 17]. Such a
national N-of-1 service could assist individual physicians in
performing and evaluating N-of-1 trials in a more appro-
priate way.
The database part of the study showed that the
proportion of youths starting stimulant treatment with an
N-of-1 trial ranged from 0.6 to 3.3% per year. No
statistically significant difference could be detected be-
tween the continuation curves of stimulant treatment after
starting with or without an N-of-1 trial. One would expect a
steeper curve when N-of-1 trials were mainly used to
discourage overenthusiastic prescribing [14]. Analogously,
one would expect a less steep curve when N-of-1 trials
were predominantly used to convince reluctant parents [11,
14]. However, the vast majority of the interviewed
physicians in the current study did not mention these
reasons for conducting an N-of-1 trial. The lack of a sound
statistical evaluation of the N-of-1 trials may also explain
why no difference was found between those who started
with or without an N-of-1 trial, as non-responders and
responders could not be distinguished accurately. Also, the
number of youths starting stimulant treatment with an N-of-
1 trial was probably too small to detect differences, if any.
Two studies about the use of N-of-1 trials for the evaluation
of existing treatment with quinine sulphate and non-
steroidal anti-inflammatory drugs reported patients pre-
ferred to continue using these drugs, despite the fact that
most patients did not clearly benefit from them [27, 28].
Therefore, when the aim of the N-of-1 trial is to identify the
efficacy of an existing treatment, it is important to negotiate
treatment continuation or cessation before starting the N-of-
1 trial [12, 28].
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Fig. 1 Continuation of stimulant
treatment in youths <20 years,
who started stimulant treatment in
2000–2003 without an N-of-1
trial (n=1,279) and with an N-of-
1 trial (n=28)
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The study presented has certain limitations that need to
be taken into account. For the first part of the study, we
used pharmacies as a starting point for our search for
physicians performing N-of-1 trials with stimulants. There-
fore, no estimations could be made about the proportion of
child psychiatrists and paediatricians in the Netherlands
actually using the N-of-1 methodology. There are two
forms of ‘non-response’ in this study. Firstly, 50% of the
pharmacists responded. Although this is not a high
percentage, all regions were represented. Another reason
concerning the inability to access physicians is that nine
pharmacists were unable or unwilling to give names of
physicians for us to interview. However, we think we
covered most of the different aspects of N-of-1 trials
procedures because no new information was obtained after
the tenth interview.
To detect N-of-1 trials with stimulants in our database,
inclusion criteria were formulated based on a consensus
discussion with pharmacists, which in theory may have lead
to an underestimation of the proportion of stimulant treat-
ments starting with an N-of-1 trial. The chosen time frame of
a maximum 2 weeks between dispension of compounded
methylphenidate capsules and placebo capsules was chosen
because none of the interviewed physicians used treatment
periods longer than 2 weeks. To investigate the effect of this
time frame we repeated the selection of N-of-1 trials using a
time frame of 3 weeks. This increased time frame lead to
inclusion of other compounded capsules with adjunct
medication (e.g. melatonin, risperidon, olanzapin, lithium)
and did not lead to the detection of any additional N-of-1
trials meeting the criteria.
An N-of-1 trial can be a useful tool in deciding whether
a stimulant treatment is a suitable treatment for the
individual patient [6, 11, 13, 14, 26]. Moreover, we think
that a well-conducted N-of-1 trial is more ethically
acceptable than the usual trial of therapy because an N-of-
1 trial is a systematic double-blind and placebo-controlled
evaluation. This is especially the case, as a significant
proportion of the 20–30% non-responders are expected to
experience adverse effects [2]. The advantage of an N-of-1
trial over the usual titration is that youth, parents and
physicians are blinded, which enhances the objective rating
of behaviour changes. Also, youth and parents are more
actively involved in the decision-making process. It has
been shown that parents were more satisfied with their
child’s treatment after participating in an N-of-1 trial than
after a normal trial of therapy, although rates of compliance
did not differ after a 6-week and 3-month follow-up [11].
We think the use of an N-of-1 trial before stimulant
treatment should be encouraged in clinical practice. More
uniformity in the protocols used would make it easier for
physicians to encompass the N-of-1 methodology in their
daily practice. More uniformity in N-of-1 protocols is also
helpful in making ready-for-use statistical tests easily
available to the physician.
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